Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Endometrial Neoplasms 2Urinary Bladder Neoplasms 1Solid Tumor 1Pathologic Complete Response 1Ovarian Neoplasms 1Hemangiosarcoma 1

Interventions

pembrolizumab 156Gemcitabine 139Capecitabine 121Paclitaxel 119Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 93Cisplatin 90Irinotecan 88Carboplatin 85Radiosurgery 83Cyclophosphamide 71Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 46Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × trastuzumab duocarmazine × Clear all
NCT04602117 2023-11-18

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

QuantumLeap Healthcare Collaborative

Phase 1 Withdrawn
BreastGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02277717 2023-08-14

First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients

Byondis B.V.

Phase 1 Completed
185 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡